TY - JOUR
T1 - Validation of the M. D. Anderson Symptom Inventory multiple myeloma module
AU - Jones, Desiree
AU - Vichaya, Elisabeth G.
AU - Wang, Xin Shelley
AU - Williams, Loretta A.
AU - Shah, Nina D.
AU - Thomas, Sheeba K.
AU - Johnson, Valen E.
AU - Champlin, Richard E.
AU - Cleeland, Charles S.
AU - Mendoza, Tito R.
N1 - Funding Information:
This work was supported by grants from the National Cancer Institute of the National Institutes of Health (P01 CA124787 to CSC and the MD Anderson Cancer Center Support Grant P30 CA016672). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. The authors thank Jeanie F. Woodruff, ELS, a medical editor employed by the Department of Symptom Research at MD Anderson, for editorial services; Gary Mobley, Katherine Gilmore, and Mary Sailors in the Department of Symptom Research at MD Anderson for data management; and Jackie Joy and Venus Ilagan for symptom and clinical data collection.
PY - 2013
Y1 - 2013
N2 - Background: The symptom burden associated with multiple myeloma (MM) is often severe. Presently, no instrument comprehensively assesses disease-related and treatment-related symptoms in patients with MM. We sought to validate a module of the M. D. Anderson Symptom Inventory (MDASI) developed specifically for patients with MM (MDASI-MM). Methods. The MDASI-MM was developed with clinician input, cognitive debriefing, and literature review, and administered to 132 patients undergoing induction chemotherapy or stem cell transplantation. We demonstrated the MDASI-MM's reliability (Cronbach α values); criterion validity (item and subscale correlations between the MDASI-MM and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EORTC MM module (QLQ-MY20)), and construct validity (differences between groups by performance status). Ratings from transplant patients were examined to demonstrate the MDASI-MM's sensitivity in detecting the acute worsening of symptoms post-transplantation. Results: The MDASI-MM demonstrated excellent correlations with subscales of the 2 EORTC instruments, strong ability to distinguish clinically different patient groups, high sensitivity in detecting change in patients' performance status, and high reliability. Cognitive debriefing confirmed that the MDASI-MM encompasses the breadth of symptoms relevant to patients with MM. Conclusion: The MDASI-MM is a valid, reliable, comprehensive-yet-concise tool that is recommended as a uniform symptom assessment instrument for patients with MM.
AB - Background: The symptom burden associated with multiple myeloma (MM) is often severe. Presently, no instrument comprehensively assesses disease-related and treatment-related symptoms in patients with MM. We sought to validate a module of the M. D. Anderson Symptom Inventory (MDASI) developed specifically for patients with MM (MDASI-MM). Methods. The MDASI-MM was developed with clinician input, cognitive debriefing, and literature review, and administered to 132 patients undergoing induction chemotherapy or stem cell transplantation. We demonstrated the MDASI-MM's reliability (Cronbach α values); criterion validity (item and subscale correlations between the MDASI-MM and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EORTC MM module (QLQ-MY20)), and construct validity (differences between groups by performance status). Ratings from transplant patients were examined to demonstrate the MDASI-MM's sensitivity in detecting the acute worsening of symptoms post-transplantation. Results: The MDASI-MM demonstrated excellent correlations with subscales of the 2 EORTC instruments, strong ability to distinguish clinically different patient groups, high sensitivity in detecting change in patients' performance status, and high reliability. Cognitive debriefing confirmed that the MDASI-MM encompasses the breadth of symptoms relevant to patients with MM. Conclusion: The MDASI-MM is a valid, reliable, comprehensive-yet-concise tool that is recommended as a uniform symptom assessment instrument for patients with MM.
KW - Assessment
KW - MDASI
KW - Multiple myeloma
KW - Symptoms
KW - Validation
UR - http://www.scopus.com/inward/record.url?scp=84873248158&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873248158&partnerID=8YFLogxK
U2 - 10.1186/1756-8722-6-13
DO - 10.1186/1756-8722-6-13
M3 - Article
C2 - 23384030
AN - SCOPUS:84873248158
SN - 1756-8722
VL - 6
JO - Journal of Hematology and Oncology
JF - Journal of Hematology and Oncology
IS - 1
M1 - 13
ER -